CA
NZ
UK
AU
IND
US
● That beat estimates by $0.50 a share.
● The combination significantly reduced the risk of death.
● Petosemtamab is a bispecific antibody targeting two cancer-cell targets.
● No specific catalyst was cited for the move.
● Full-year guidance was kept unchanged.
● The deal would value the company at about $1.4 billion.
● Revenue and trading volume both hit records.
● Germany's DAX index finished higher the same day.
● The move rode a broader wave of buying in AI-power names.
● Two officials dissented in favor of a rate hike.
Please wait processing your request...